Drug Trial Radar · NCT07476729
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)
Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
750
Planned (sponsor's estimate)
Start
Sep 1, 2026
Primary completion
Mar 31, 2033
Study completion Mar 31, 2033
Sponsor
- Lead sponsor
- Charite University, Berlin, GermanyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 17, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The IntReALL BCP 2020 study aims to review recent developments and findings regarding chemoimmunotherapy with inotuzumab and immunotherapy with blinatumomab and to increase the use of promising new immunotherapeutic drugs as replacements for toxic SOC chemotherapy elements. The IntReALL BCP 2020 study has the potential to improve CR and EFS rates for all SR and HR groups, as well as for patients with IEM recurrence, by replacing toxic chemotherapy with targeted, less toxic immunotherapy strategies, and could establish these new approaches as SOC for children with relapsed BCP ALL in the future.
Conditions
- B-Cell Acute Lymphoblastic Leukaemia
Interventions
Inotuzumab ozogamicin (INO)Drug
Antibody Drug Conjugate (Inotuzumab)
BlinatumomabDrug
Bispecific t-cell enganger BiTE
Primary outcomes
What the sponsor says the trial is designed to measure.
- SR induction EFSTime frame: From enrollment until 2 years after end of treatment
- SR-MRD good response consolidation DFSTime frame: From enrollment until 2 years after end of treatment
- HR with CR2 consolidation DSFTime frame: From enrollment until 2 years after end of treatment
- Isolated extramedullary manifestations: EFSTime frame: From enrollment until 2 years after end of treatment
- SR induction: Pharmacokinetics InotuzumabTime frame: from enrollment until day 28
Locations
21 sites in 21 countries. Site status is shown where the registry gives one.
St. Anna Kinderspital GmbH
Vienna, Austria · Recruiting
Ghent University Hospital
Ghent, Belgium · Not yet recruiting
Fakultni Nemocnice V Motole
Prague, Czechia · Recruiting
Rigshospitalet
Copenhagen, Denmark · Recruiting
HUS Helsinki University Hospital
Helsinki, Finland · Not yet recruiting
CHU de NICE, Hôpital L'ARCHET
Nice, France · Recruiting
Charité - Universitätsmedizin Berlin
Berlin, Germany · Recruiting
Semmelweis University
Budapest, Hungary · Not yet recruiting
Tel Aviv Sourasky Medical Centre Dana-Dwek Children's Hospital
Tel Aviv, Israel · Not yet recruiting
Ospedale Pediatrico Bambino Gesu
Rome, Italy · Not yet recruiting
Prinses Máxima Centrum
Utrecht, Netherlands · Recruiting
Oslo University Hospital
Oslo, Norway · Recruiting
University Wroclaw
Wroclaw, Poland · Not yet recruiting
Instituto Português de Oncologia de Lisboa
Lisbon, Portugal · Not yet recruiting
Fundeni Clinical Institute, Pediatric Clinic Fundeni
Bucharest, Romania · Not yet recruiting
Univerzity Komenského a Národného
Bratislava, Slovakia · Not yet recruiting
University Medical Centre Ljubljana
Ljubljana, Slovenia · Not yet recruiting
University Clinical Hospital Virgen De La Arrixaca
Murcia, Spain · Recruiting
Karolinska University Hospital
Solna, Sweden · Recruiting
University Children's Hospital
Zurich, Switzerland · Not yet recruiting
Acıbadem University
Istanbul, Turkey (Türkiye) · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.